TNF İnhibitörlerine İntolerans/ Yetersiz Yanıtlı Romatoid Artrit Hastalarında Sarilumumab Kullanımı Hasta- Bildirimli Sonuçları İyileştirmektedir
RMD Open 2017;3:e000416. DOI:10.1136/rmdopen-2016-000416
Evidence is presented that treatment with sarilumab demonstrates patient-reported benefits in TNF-IR patients with moderate to severe RA. These improvements complement the clinical efficacy previously reported for sarilumab, and are consistent with those seen in the MOBILITY trial (MTX-IR patients)1, yet in a more difficult-to-treat population.Data were analysed from the 24-week Phase 3 TARGET randomised controlled trial in adult patients with active RA and previous inadequate response or intole...